Biotechnology

BioNTech experiences a decline in quarterly profits but surpasses market expectations, showcasing resilience amid strategic shifts. Revenue decreased from €1.479 billion to €1.19 billion but still outperformed projections. The waning…

Oryzon Genomics' stock surged by 21% to 3.69 euros, marking a 140% increase this year, with market capitalization exceeding 230 million euros. The rise is driven by positive Phase IIa…